Search

CN-121987735-A - Traditional Chinese medicine composition for treating irritable bowel syndrome after infection and preparation method and application thereof

CN121987735ACN 121987735 ACN121987735 ACN 121987735ACN-121987735-A

Abstract

The invention belongs to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating irritable bowel syndrome after infection, and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials, by weight, 10-15 parts of bighead atractylodes rhizome, 10-20 parts of white paeony root, 3-7 parts of dried orange peel, 5-15 parts of divaricate saposhnikovia root, 10-20 parts of cotton residue leaves, 10-20 parts of plumeria rubra, 5-15 parts of kapok, 25-35 parts of glabrous greenbrier rhizome and 5-15 parts of albizia flower. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotype and depression symptoms of rats with PI-IBS liver depression and spleen deficiency syndrome, lighten visceral hypersensitivity, restore colon tight connection structure and cell desmosome structure, up regulate cell TJ protein expression, restore blood Th1/Th2 immune imbalance, reduce pro-inflammatory factor (TNF-alpha) level in colon tissues, and up regulate LPS, DAO and D-LA level in serum. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the syndrome of liver depression and spleen deficiency of irritable bowel syndrome after infection.

Inventors

  • QIN SHUMIN
  • YIN JINJIN
  • LI SIYA
  • LIU TIANWEN
  • XU JINGYI

Assignees

  • 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院）

Dates

Publication Date
20260508
Application Date
20260210

Claims (8)

  1. 1. The traditional Chinese medicine composition for treating the irritable bowel syndrome after infection is characterized by comprising, by weight, 10-15 parts of bighead atractylodes rhizome, 10-20 parts of white paeony root, 3-7 parts of dried orange peel, 5-15 parts of divaricate saposhnikovia root, 10-20 parts of folium bubali, 10-20 parts of plumeria rubra, 5-15 parts of kapok, 25-35 parts of glabrous greenbrier rhizome and 5-15 parts of flos albiziae.
  2. 2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition comprises, by weight, 12 parts of bighead atractylodes rhizome, 15 parts of white paeony root, 5 parts of dried orange peel, 10 parts of divaricate saposhnikovia root, 15 parts of cotton residue leaf, 15 parts of plumeria rubra, 9 parts of kapok, 30 parts of glabrous greenbrier rhizome and 10 parts of albizia flower.
  3. 3. The traditional Chinese medicine composition according to claim 1 or 2, wherein the bighead atractylodes rhizome is stir-fried bighead atractylodes rhizome and the white paeony root is stir-fried white paeony root.
  4. 4. The traditional Chinese medicine composition according to claim 1 or 2, wherein pharmaceutically acceptable auxiliary materials can be added.
  5. 5. The traditional Chinese medicine composition according to claim 1 or 2, wherein the traditional Chinese medicine composition is in the form of decoction, granules, powder, tablets, pills or capsules.
  6. 6. The method for preparing the traditional Chinese medicine composition for treating irritable bowel syndrome after infection according to any one of claims 1-5, comprising the following steps: soaking the raw materials in 4-8 times of water for 20-40 min times, boiling with strong fire for 30-40 min times, boiling with slow fire for 30-40 min times, filtering, repeatedly decocting the residue for 1-2 times, and mixing filtrates.
  7. 7. Use of a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome according to any one of claims 1-5 in the preparation of a medicament for treating post-infection irritable bowel syndrome.
  8. 8. The use of a Chinese medicinal composition for the treatment of post-infection irritable bowel syndrome according to any one of claims 1-5 in the manufacture of a medicament for the treatment of post-infection irritable bowel syndrome with liver depression and spleen deficiency.

Description

Traditional Chinese medicine composition for treating irritable bowel syndrome after infection and preparation method and application thereof Technical Field The invention belongs to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating irritable bowel syndrome after infection, and a preparation method and application thereof. Background Irritable bowel syndrome (irritable bowel syndrome, IBS) is the most common functional gastrointestinal disease in clinic, and Post-infection irritable bowel syndrome (Post-INFECTIVE IRRITABLE BOWEL SYNDROME, PI-IBS) is a common IBS subtype, and is characterized in that after the symptoms of acute gastrointestinal infection are relieved, patients still continuously present with symptoms of discomfort such as abdominal pain, diarrhea and the like, and the symptoms belong to the category of diarrhea type irritable bowel syndrome (diarrhea-predominant irritable bowel syndrome, IBS-D), the existing researches have clear specific pathogen induction effect of PI-IBS, however, after the acute infection process of the digestive tract is finished, the pathological mechanism of persistent abdominal pain and abnormal defecation is still incompletely resolved, so that the acute gastrointestinal infection is lack of clear and effective treatment, and heavy economic and living burden is brought to families and society. At present, the PI-IBS is mainly treated in a symptomatic manner clinically, for example, diarrhea symptoms are relieved by adopting antidiarrheal montmorillonite powder, loperamide and the like, intestinal smooth muscle spasm and abdominal pain symptoms are relieved by adopting atropine and pinaverium bromide, and depression symptoms are relieved by adopting antidepressant amitriptyline. However, western medicines are often unsatisfactory in clinical treatment effects, and the symptoms and root causes are not cured. The traditional Chinese medicine has unique advantages in treating IBS due to multiple target sites, small side effects. IBS belongs to the categories of 'abdominal pain', 'diarrhea', 'constipation' and the like in traditional Chinese medicine, and is one of the dominant diseases for preventing and treating traditional Chinese medicine. In recent years, research reports on intervention of traditional Chinese medicine therapy on functional gastroenteropathy such as IBS and the like are frequently reported internationally. The traditional Chinese medicine compositions for treating IBS clinically at present comprise Siqisan, bupleurum soothing liver powder, ginseng, poria, bighead atractylodes rhizome powder, pain relieving and calming granules and the like, however, for PI-IBS, the traditional Chinese medicine compositions often have difficulty in achieving satisfactory curative effects. Therefore, aiming at the unique pathogenesis of PI-IBS, a traditional Chinese medicine composition capable of effectively treating PI-IBS is needed to be developed so as to meet clinical medication requirements. Disclosure of Invention The first object of the invention is to provide a traditional Chinese medicine composition for treating irritable bowel syndrome after infection, the second object of the invention is to provide a preparation method of the traditional Chinese medicine composition, and the third object of the invention is to provide application of the traditional Chinese medicine composition. According to a first aspect of the invention, a traditional Chinese medicine composition for treating irritable bowel syndrome after infection is provided, which comprises, by weight, 10-15 parts of bighead atractylodes rhizome, 10-20 parts of white peony root, 3-7 parts of dried orange peel, 5-15 parts of divaricate saposhnikovia root, 10-20 parts of cotton residue leaf, 10-20 parts of plumeria rubra, 5-15 parts of kapok, 25-35 parts of glabrous greenbrier rhizome and 5-15 parts of albizia flower. The invention considers that the weakness of the spleen and the stomach and the liver failure and the diarrhea exist in the whole pathogenesis of diarrhea type irritable bowel syndrome (IBS-D), and the liver depression and the spleen deficiency are the core pathogenesis. After infection, irritable bowel syndrome (PI-IBS) not only shows core symptoms such as bellyache, diarrhea and the like typical to IBS-D, but also shows unique clinical heterogeneity due to infectious diseases. After infection, the body fails to completely clear pathogens, the internal pathogenic factors cannot be completely cleared, the residual pathogenic factors and vital qi struggle with each other, and a continuous pathological state of struggle between vital qi and pathogenic factors is caused, which causes repeated attacks and lasting of clinical symptoms. The struggle between the healthy qi and the pathogenic factors makes the treatment of PI-IBS more complex, and the healthy qi and pathogenic factors in the body are further cleared